Topo II Inhibitor

Topo II Inhibitors (140):

Cat. No.	Product Name	Effect	Purity

HY-W715630

Salvicine	Inhibitor
Salvicine is a DNA topoisomerase II inhibitor (IC₅₀=3 μM). Salvicine increases the interaction between DNA and Topo II by interacting with the ATPase domain, inhibiting DNA degradation and ATP hydrolysis. Salvicine has anticancer activities, including inhibiting Topo II, causing DNA damage, overcoming multidrug resistance, and inhibiting tumor cell adhesion.

HY-182054

Topoisomerase ll/ME-1-IN-1	Inhibitor
Topoisomerase ll/ME-1-IN-1 (Compound 7a) is a Topoisomerase ll and ME-1 inhibitor with an IC₅₀ of 5.03 μM against Topoisomerase ll. Topoisomerase ll/ME-1-IN-1 functionally inhibits the activity of Topoisomerase II and functionally blocks the activity of ME-1. Topoisomerase ll/ME-1-IN-1 induces Autophagy by upregulating the expression of Beclin-1 and LC3-II. Topoisomerase ll/ME-1-IN-1 promotes Apoptosis. Topoisomerase ll/ME-1-IN-1 exhibits antiproliferative activity against breast cancer cells and shows no toxicity to normal mammary epithelial cells. Topoisomerase ll/ME-1-IN-1 can be used in studies related to breast cancer (including triple-negative breast cancer).

HY-117613

A-74932 hydrochloride	Inhibitor
A-74932 hydrochloride is a potent Top II inhibitor with antitumor activity. A-74932 hydrochloride inhibits the catalytic activity of mammalian DNA topoisomerase II. A-74932 hydrochloride can be used for cancer research.

HY-146138

EGFR-IN-57	Inhibitor
EGFR-IN-57 (Compound 25a) is a potent, orally active EGFR-TK inhibitor with an IC₅₀ of 0.054 µM. EGFR-IN-57 also inhibits VEGFR-2, CK2α, topoisomerase IIβ and tubulin polymerization with IC₅₀ values of 0.087, 0.171, 0.13 and 3.61 µM, respectively. EGFR-IN-57 induces cell cycle arrest at G2/M and pre-G1 phases. EGFR-IN-57 induces cancer cell apoptosis.

HY-146020

Topoisomerase IIα-IN-1	Inhibitor
Topoisomerase IIα-IN-1 (compound 2) is a potent DNA-binding ligands and topoisomerase IIα inhibitor. Topoisomerase IIα-IN-1 exhibits high antiproliferative activity against human cancer cell lines.

HY-W031307

Topoisomerase IIα-IN-8	Inhibitor
Topoisomerase IIα-IN-8 (compound 15) is a weak human DNA topoisomerase IIa (htIIa) inhibitor, with an IC₅₀ of 462 ± 38.0 μM.

HY-109855

CP-67015	Inhibitor
CP-67015, a quinolone antibiotic, is a potent topoisomerase II inhibitor. CP-67015 is a positive direct-acting mutagen in mammalian cells with both gene and chromosomal level effects.

HY-161628

Tapcin	Inhibitor
Tapcin is a dual inhibitor for topoisomerase I and topoisomerase II, with IC₅₀ of 203 and 71 nM. Tapcin inhibits proliferations of cancer cells A-375, HeLa, Huh7.5, U2-OS, A549, Caco-2 and HT29, with IC₅₀s of 441, 1.04, 40.5, 0.002, 0.006, 0.287 and 0.842 nM, respectively. Tapcin exhibits antitumor activity in HT29 xenograft model.

HY-163118

Topoisomerase II inhibitor 17	Inhibitor
Topoisomerase II inhibitor 17 (compound 4c) is an inhibitor of thiazolopyrimidine topoisomerase (Topoisomerase) Top II (IC₅₀: 0.23 μM). Topoisomerase II inhibitor 17 can significantly cause cell cycle disruption and apoptosis.

HY-118823

Amonafide L-malate	Inhibitor
Amonafide L-malate is a topoisomerase II inhibitor and DNA intercalator that induces Apoptotic signaling by blocking the binding of Topo II to DNA.

HY-180509

Topoisomerase I/IIα-IN-1	Inhibitor
Topoisomerase I/IIα-IN-1 (Compound 20i) is a Topoisomerase I/IIα inhibitor. MDM2-IN-27 can effectively block the inhibitory effect of MDM2 on p53, thereby activating the p53 pathway. MDM2-IN-27 has relatively poor anti-proliferative activity against breast cancer, colon cancer, and cutaneous squamous cell carcinoma.

HY-143402

Topoisomerase I/II inhibitor 2	Inhibitor
Topoisomerase I/II inhibitor 2 (compound 1a) is a potent Topoisomerase inhibitor (IC₅₀= 9.82 μM on Huh7 cells and 6.83 μM on LM9 cells). Topoisomerase I/II inhibitor 2 has dual inhibition on DNA topoisomerase I/II, also can obviously reduce the growth of xenograft tumor in mice model. Topoisomerase I/II inhibitor 2 has the potential value in researching liver cancer.

HY-108352

HU 331	Inhibitor
HU 331 (HU 331) is a highly specific Topoisomerase II inhibitor with anticancer activity. HU 331 has shown promising inhibitory effects on human cancer cell lines in vitro and human tumor xenografts in nude mice in vivo.

HY-170912

Topo I/II-IN-2	Inhibitor
Topo I/II-IN-2 (Compound 3g) is an inhibitor of Topo I and Topo II. Topo I/II-IN-2 inhibits NCI-H446 cells and NCI-H1048 cells with IC₅₀s of 1.30 μM and 1.42 μM, respectively. Topo I/II-IN-2 induces mitochondrial Apoptosis, mitochondrial dysfunction and activity generation. Topo I/II-IN-2 inhibits the PI3K/Akt/mTOR pathway. Topo I/II-IN-2 prevents SCLC (small cell lung cancer) cell proliferation, invasion, and migration in vitro. .

HY-120185

Saintopin	Inhibitor
Saintopin is an antitumor antibiotic. Saintopin is also an inhibitor of DNA topoisomerases I and II. Saintopin induces DNA cleavage.

HY-101647A

Intoplicine dimesylate	Inhibitor	98.28%
Intoplicine (RP 60475) dimesylate, an antitumor derivative in the 7H-benzo[e]pyrido[4,3-b]indole series, is a DNA topoisomerase I and II inhibitor. Intoplicine dimesylate strongly binds DNA (K_A = 2 x 10⁵ /M) and thereby increases the length of linear DNA.

HY-146163

Topoisomerase II inhibitor 7	Inhibitor
Topoisomerase II inhibitor 7 (compound 3a) is a potent inhibitor of topoisomerase II alpha subtype, with an IC₅₀ of 3.19 μM. Topoisomerase II inhibitor 7 can induce cell cycle arrest and apoptosis.

HY-169628

Topoisomerase I/II inhibitor 7	Inhibitor
Topoisomerase I/II inhibitor 7 (Compound 5h) is a Topoisomerase I/II inhibitor.

HY-175853

Topoisomerase II-IN-24	Inhibitor
Topoisomerase II-IN-24 is a Topoisomerase IIα inhibitor with an IC₅₀ of 41.67 μM. Topoisomerase II-IN-24 can inhibit cancer cells proliferation, induce G2/M phase arrest and induce apoptosis. Topoisomerase II-IN-24 can be used for the research of cancer, such as colon cancer.

HY-152479

Topoisomerase IIα-IN-7	Inhibitor
Topoisomerase IIα-IN-7 is an DNA topoisomerase IIα inhibitor with an IC₅₀ value of 7.7 µM. Topoisomerase IIα-IN-7 has broad-spectrum cytotoxicity to leukemia, lung, colon, melanoma, ovarian, kidney, prostate and breast cancer cells. Topoisomerase IIα-IN-7 has metabolic stability.

Name
Email *

	Sorry, but the email address you supplied was invalid.